Drug, bio-affecting and body treating compositions inventions 09/07

20070225246 - O-acetyl-adp-ribose non-hydrolyzable analogs: Compounds, compositions and methods for modulating cell death in target cells, particularly cancer cells are provided. The compounds are analogs of O-acetyl-ADP-ribose (OAADPr).... Agent: Brinks Hofer Gilson & Lione

20070225202 - Methods for identifying modulators of active kit tyrosine kinase receptor: The present invention relates to cell-based assays useful for screening for modulators, such as inhibitors, of activated mutant KIT tyrosine kinase receptors, which are associated with mast cell-related disorders, such as mastocytosis and various types of cancer. The invention further provides for the treatment of mast cell-related disorders with an... Agent: Marshall, Gerstein & Borun LLP

20070225206 - Biomarkers for osteoarthritis: Methods are provided for evaluating osteoarthritis (OA), for example for diagnosing OA, to confirm a diagnosis of OA, to assess or prognose progression of OA, determining the severity of a subject who has OA, and determining a subject's risk of developing OA in the future, as are arrays and kits... Agent: Klarquist Sparkman, LLP

20070225209 - Compositions and methods for treating neurological disorders and diseases: The present invention generally relates to methods and compositions for treating neurological disorders and diseases. In addition, methods for selecting therapeutic agents useful for treating neurological disorders and diseases are provided.... Agent: Myriad Genetics Inc. Intellecutal Property Department

20070225207 - Group 1 mite polypeptide variants: This invention concerns variants of a group 1 mite polypeptide, wherein the mature polypeptide of the variants comprise one or more mutations in the positions or corresponding to positions consisting of P11, I14, D15, L16, M19-P24, Q28, F37, S38, T43, A46-A49, Q53-L57, V63, A66-H69, H72, D74-R77, I80, Y82, Q84, H85,... Agent: Novozymes North America, Inc.

20070225204 - Interferon-alpha polypeptides and conjugates: The present invention provides interferon-alpha polypeptides and conjugates, and nucleic acids encoding the polypeptides. The invention also includes compositions comprising these polypeptides, conjugates, and nucleic acids; cells containing or expressing the polypeptides, conjugates, and nucleic acids; methods of making the polypeptides, conjugates, and nucleic acids; and methods of using the... Agent: Maxygen, Inc. Intellectual Property Department

20070225205 - Interferon-alpha polypeptides and conjugates: The present invention provides interferon-alpha polypeptides and conjugates, and nucleic acids encoding the polypeptides. The invention also includes compositions comprising these polypeptides, conjugates, and nucleic acids; cells containing or expressing the polypeptides, conjugates, and nucleic acids; methods of making the polypeptides, conjugates, and nucleic acids; and methods of using the... Agent: Maxygen, Inc. Intellectual Property Department

20070225203 - Method and composition for preventing multiple organ dysfunction syndrome: One aspect of the present invention relates to a method of preventing multiple organ dysfunction syndrome in a mammal suffering from trauma, said method comprising enterally administering to said mammal, within 24 hours of the occurrence of the trauma, (i) digestible water soluble carbohydrates and (ii) a liver guanosine-5′-triphosphate (GTP)... Agent: The Webb Law Firm, P.C.

20070225208 - Use of fibrin for separating body organs: The present invention relates to the use of coagulant or gellifying substances for administration into body sites with the aim of obtaining the temporary separation of said organs. The invention also relates to a method for the separation of body sites and a related administration kit using said substances.... Agent: Dickstein Shapiro LLP

20070225211 - Methods and formulations for increasing intestinal function: A method for increasing intestinal function is provided. The method comprising orally and/or enterally administering to a subject in need thereof a therapeutically effective amount of insulin, thereby increasing intestinal function.... Agent: Martin D. Moynihan Prtsi, Inc.

20070225210 - Therapeutic vaccine compositions for the treatment of type 1 diabetes: The invention concerns therapeutic vaccine compositions that comprise modified Insulin B chain components suitable for use as immunogenic agents for treatment and prevention of Type 1 Diabetes.... Agent: Thomas Hoxie, Esq. Hoxie & Tso LLP

20070225212 - Use of a peptide: The invention employs GLP-1 (7-37), GLP-1(7-36)amide, and certain related compounds in combination with an oral hypoglycaemic agent for treating diabetes mellitus.... Agent: Novo Nordisk, Inc. Patent Department

20070225213 - Nucleic acid carriers for delivery of therapeutic agents: Nucleic acid drug carriers comprise a nucleic acid carrier complexed with a drug, wherein the nucleic acid carrier and the drug are associated non-covalently, and optionally other agents such as spacer, transfection agents, and targeting agents. The nucleic acid drug complex are discovered to have permissive or refractory uptake depending... Agent: Matthew K. Kosak

20070225214 - Use of osteopontin for the treatment and/or prevention of neurologic diseases: The invention relates to the use of osteopontin, or of an agonist of osteopontin activity, for treatment or prevention of a neurologic diseases.... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20070225215 - Modulation of cartilage homeostasis by active domains of cell binding extracellular matrix molecules: A linear or cyclic peptide and the use of said peptide in medicine and especially in the manufacture of a medicament for the treatment and/or prophylaxis of a disease associated with inflammatory mediated cartilage destruction. The minimal core sequence of the linear or cyclic peptide is WLEAK. Alternatives are WLEAR... Agent: Lynn E Barber

20070225216 - Cyclic peptides for modulating growth of neo-vessels and their use in therapeutic angiogenesis: The present disclosure teaches analogs of human chemokines and methods of using them in the prevention, treatment, and ameliorization of diseases that can benefit from therapeutic angiogenesis. The teachings are generally directed to compositions comprising SDF-1 mimetics, as well as methods that include the use of SDF-1 mimetics to induce... Agent: Perkins Coie LLP

20070225217 - Methods, compositions, and kits for the treatment of medical conditions: The invention features methods, compositions, and kits for treating an immunoinflammatory disorder, an ophthalmic disorder, a musculoskeletal disorder or pain associated therewith, a periodontal disease, or a disease or condition associated with an increased serum CRP level.... Agent: Clark & Elbing LLP

20070225220 - Antimicrobial composition: An antimicrobial composition comprising (a) a cationic surfactant derived from the condensation of fatty acids and esterified dibasic amino acids, such as lauric arginate and (b) an antibiotic, such as of β-lactam antibiotics, polypeptides, quinolones. The composition may be used as a stand alone antimicrobial formulation, or in combination with... Agent: Philip S. Johnson Johnson & Johnson

20070225228 - Blockade of gamma-secretase activity to promote myelination by oligodendrocytes: Methods are provided for enhancing myelination. Myelination is enhanced by administration of agents that are inhibitors of γ-secretase. Methods of screening for pharmaceutically active compounds that enhance myelination, and for genes involved in myelination are also provided.... Agent: Bozicevic, Field & Francis LLP

20070225226 - C-reactive protein apheresis: The present invention provides ligands that can bind CRP with high affinity and high specificity. The present invention also provides a method of treating a condition of elevated CRP through apheresis, by reducing CRP level via its binding to a CRP-specific ligand ex vivo. Systems of performing apheresis to reduce... Agent: Foley And Lardner LLP Suite 500

20070225218 - Extracellular messengers: Various embodiments of the invention provide human extracellular messengers (EXMES) and polynucleotides which identify and encode EXMES. Embodiments of the invention also provide expression vectors, host cells, antibodies, agonists, and antagonists. Other embodiments provide methods for diagnosing, treating, or preventing disorders associated with aberrant expression of EXMES.... Agent: Foley And Lardner LLP Suite 500

20070225219 - Intramedullary drug delivery device and method of treating bone fractures: An intramedullary drug delivery device is disclosed and can be inserted within a bone canal of a bone. The intramedullary drug delivery device can include a housing. A drug delivery region can be established along the housing. Also, the drug delivery region can be configured to substantially span a fracture... Agent: Larson Newman Abel Polansky & White, LLP

20070225227 - Lipoparticles comprising ion channels, methods of making and using the same: The present invention relates to the use of lipoparticles, virus-like particles, and viruses. The present invention also relates to testing ion channel function and modulators of ion channels.... Agent: Morgan, Lewis & Bockius LLP

20070225221 - Methods of treatment using specific binding agents of human angiopoietin-2: Disclosed are peptides that bind to Ang-2. Also disclosed are peptibodies comprising the peptides, methods of making such peptides and peptibodies, and methods of treatment using such peptides and peptibodies.... Agent: Marshall, Gerstein & Borun LLP

20070225223 - Modified vitamin k-dependent polypeptides: The invention provides vitamin K-dependent polypeptides with enhanced membrane binding affinity. These polypeptides can be used to modulate clot formation in mammals. Methods of modulating clot formation in mammals are also described.... Agent: Fish & Richardson P.C.

20070225224 - Modified vitamin k-dependent polypeptides: The invention provides vitamin K-dependent polypeptides with enhanced membrane binding affinity. These polypeptides can be used to modulate clot formation in mammals. Methods of modulating clot formation in mammals are also described.... Agent: Fish & Richardson P.C.

20070225229 - N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators: Compounds of structural formula I are modulators of the androgen receptor (AR) in a tissue selective manner. These compounds are useful in the enhancement of weakened muscle tone and the treatment of conditions caused by androgen deficiency or which can be ameliorated by androgen administration, including osteoporosis, osteopenia, glucocorticoid-induced osteoporosis,... Agent: Merck And Co., Inc

20070225222 - Use of heparin-binding domain of fibronectin for diagnosis and treatment of cancer: The FNIII13 domain of fibronectin and smaller fragments thereof have a tumour cell proliferation inhibitory effect. Compositions are provided comprising fragments of fibronectin having the FNIII 13 domain and fragments thereof. A system comprising cells exposed to fibronectin and caused to proliferate by the presence of tenascin are used as... Agent: Novartis Corporate Intellectual Property

20070225225 - Use of natriuretic peptide receptor antagonists to treat ocular, otic and nasal edemetous conditions: Methods and compositions to treat edematous ocular, otic and nasal conditions are described.... Agent: Alcon

20070225230 - Vehicle for the transport of a chosen molecule to a cell: Vehicle for the transport of a chosen molecule to a cell, comprising a SAINT-molecule which is bound to the chosen molecule by means of an electrostatic interaction, in which the SAINT-molecule is coupled to the linker molecule and the linker molecule is coupled to the cell specific ligand and in... Agent: Peacock Myers, P.C.

20070225231 - Methods for inhibiting immune complex formation in a subject: Polypeptides and other compounds that can bind specifically to the CH2-CH3 cleft of an immunoglobulin molecule, and methods for using such polypeptides and compounds to inhibit Fc-mediated immune complex formation, are described.... Agent: Fish & Richardson P.C.

20070225232 - Tetrahydro-imidazo [1,5-a] pyridyin derivatives as aldosterone synthase inhibitors: The application relates to novel heterocyclic compounds of the general formula (I) in which R, R1, R2, X, Y, Z and n have the meanings defined in the description, to a process for their preparation and to the use of these compounds as medicaments, in particular as aldosterone synthase inhibitors.... Agent: Wenderoth, Lind & Ponack, L.L.P.

20070225233 - Reducing the risk of chronic lung disease in infants: Described herein is a method for reducing the risk of chronic lung disease in an infant suffering from respiratory distress syndrome by administering to the infant a combination of a corticosteroid having a high local to systemic anti-inflammatory activity (e.g., budesonide) and a lung surfactant.... Agent: Fish & Richardson PC

20070225235 - Methods for the prevention and/or the treatment of glutamate cytotoxicity: The present invention relates to the use of beta-naphthoquinone derivatives, and salts thereof, for the prevention and/or the treatment of glutamate cytotoxicity. It further relates to the use of beta-naphthoquinone derivatives, and salts thereof, for preventing and/or treating glutamate induced neurological disorders. Additionally, it concerns the use of beta-naphthoquinone derivatives,... Agent: Buchanan, Ingersoll & Rooney PC

20070225234 - Topical formulation of oil-in-water type as a carrier for providing a reduced irritant effect: A topical formulation of the oil-in-water type comprising an oily material, an aqueous phase and an emulsifier, wherein the emulsifier is a galactolipid material, as a carrier for providing a reduced irritant effect of an incorporated active substance on the skin. New topical formulations are also described.... Agent: Ralph A. Dowell Of Dowell & Dowell P.C.

20070225236 - Methods for the prevention and/or the treatment of glutamate cytotoxicity: The present invention relates to the use of beta-naphthoquinone derivatives, and salts thereof, for the prevention and/or the treatment of glutamate cytotoxicity. It further relates to the use of beta-naphthoquinone derivatives, and salts thereof, for preventing and/or treating glutamate induced neurological disorders. Additionally, it concerns the use of beta-naphthoquinone derivatives,... Agent: Buchanan, Ingersoll & Rooney PC

20070225237 - Methods for the prevention and/or the treatment of glutamate cytotoxicity: The present invention relates to the use of beta-naphthoquinone derivatives, and salts thereof, for the prevention and /or the treatment of glutamate cytotoxicity. It further relates to the use of beta-naphthoquinone derivatives, and salts thereof, for preventing and/or treating glutamate induced neurological disorders. Additionally, it concerns the use of beta-naphthoquinone... Agent: Buchanan, Ingersoll & Rooney PC

20070225238 - Inhibitors of carbonyl reductase for treatment using anthracyclines: Compositions of matter and methods of using the compositions of matter are disclosed for preventing or reducing cardiotoxicity during or after cancer treatment with anthracycline drugs, and preventing or reducing resistance to anthracycline drugs, both of which are believed to be caused by human enzyme carbonyl reductase. Thus, the compositions... Agent: Pedersen & Company, PLLC

20070225239 - Pna-neamine conjugates and methods for producing and using the same: The present invention relates to methods and compositions pertaining to conjugates composed of a peptide nucleic acid (PNA) moiety and a neamine derivative moiety. Methods for using such conjugates for modulating the activity of a target nucleic acid molecule and for preventing or treating a disease associated with an aberrant... Agent: Licatas & Tyrrell

20070225244 - Compositions comprising genome segments and methods of using the same: Methods of treating an individual who has a disease or disorder associated with one or more genetic mutations or undesirable alleles in genomic DNA of the individual, or preventing an individual from developing a disease or disorder associated with one or more genetic mutations or undesirable alleles in genomic DNA... Agent: Pepper Hamilton LLP

20070225242 - Method and composition for treating and preventing tumor metastasis in vivo: Methods, compositions and kits are provided for effectively treating and preventing cancer metastasis in vivo and for increasing survival of subjects burdened with metastatic tumors by targeting a lysyl oxidase or its modulator, especially human lysyl oxidase. Also provided are methods for identifying lysyl oxidase inhibitors and the use of... Agent: Peters Verny , L.L.P.

20070225240 - Screening assay and treatment: The invention relates to screening assays for the identification of agents which modulate the activity of polypeptides which affect the apoptotic activity of the tumour suppressor protein p53 and including gene therapy vectors comprising p53 and antibodies that bind phosphorylated epitopes.... Agent: Klarquist Sparkman, LLP

20070225241 - Tfiis and gdown1 as targets for cancer therapy: The present invention concerns cancer therapy related to the targeting of at least one core transcription factor. In particular, the compositions and methods of the invention concern targeting TFIIS, GDOWN1, or both for cancer therapy. In specific aspects, TFIIS and/or GDOWN1 inhibitors are employed for breast, prostate, pancreatic, and/or lung... Agent: Fulbright & Jaworski, LLP

20070225243 - Treatment of cancer using cytokine-expressing polynucleotides and compositions therefor: The present invention provides a pharmaceutical composition, comprising a non-infectious, non-integrating polynucleotide construct comprising a polynucleotide encoding an interferon ω and one or more cationic compounds. The present invention also provides methods of treating cancer in a mammal, comprising administering into a tissue of the mammal a non-infectious, non-integrating polynucleotide... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20070225245 - Viral vector driven mutant bacterial cytosine deaminase gene and uses thereof: The instant invention has developed viral vectors encoding a mutant bacterial cytosine deaminase (bCD) gene, which have a higher affinity for cytosine than wild type bCD (bCDwt). The purpose of the present invention was to evaluate cytotoxicity in vitro and therapeutic efficacy in vivo of these vectors in combination with... Agent: Benjamin Aaron Adler Adler & Associates

20070225247 - Process for preparing an a2a-adenosine receptor agonist and its polymorphs: Disclosed is a synthesis suitable for large scale manufacture of an A2A-adenosine receptor agonist, and also relates to polymorphs of that compound, and to methods of isolating a specific polymorph.... Agent: Cv Therapeutics, Inc.

20070225249 - 2'-fluoronucleoside phosphonates as antiviral agents: The present invention includes compounds and compositions of R-2′-fluoronucleoside phosphonates, as well as methods to treat HIV, HBV, HCV or abnormal cellular proliferation comprising administering said compounds or compositions.... Agent: Nutter Mcclennen & Fish LLP

20070225248 - Oral dosage forms of gemcitabine derivatives: The present invention relates to oral dosage forms of certain long chain saturated and monounsaturated fatty acid derivatives of 2′,2′-difluorodeoxycytidine (Gemcitabine). In particular, the present invention relates to the use of the said gemcitabine derivatives or a pharmaceutical acceptable salt thereof for preparing an oral dosage form ameliorating compliance in... Agent: Fitzpatrick Cella Harper & Scinto

20070225250 - Cobalamin compositions for the treatment of cancer: Compositions are provided that contain a combination of a nitric oxide-cobalamin complex along with at least one cobalamin drug conjugate, together with methods for their use in the treatment of neoplastic disease.... Agent: Proskauer Rose LLP

20070225252 - Ketogenic saccharides: A novel ketogenic compound is provided having general formula (R(OCH(CH3)CH2C(O))nO)m-A wherein n is a integer between 1 and 10, m is an integer of 1 to 200,000, A is a monsaccharide, polysaccharide or oligosaccharide residue and R is selected from the group consisting of H, C1-C6 alkyl and acetoacetyl-.... Agent: Nixon & Vanderhye, PC

20070225251 - Method for treating or inhibiting the effects of injuries or diseases that result in neuronal degeneration: Oligosaccharides, and in particular disaccharides, which are degradation products of chondroitin sulfate proteoglycan are effective for use in treating, inhibiting, or ameliorating the effects of injuries or diseases or disorders that result in or are caused by neuronal degeneration or of disorders resulting in mental and cognitive dysfunction.... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20070225253 - Use of a trioxopyrimidine for the treatment and prevention of bronchial inflammatory diseases: The invention provides the use of a trioxopyrimidine compound having an inhibitory activity against MMP-1, MMP-2, MMP-3, MMP-9 and MMP-14 defined as a) an IC50 value of less than 5 μM for MMP-2, MMP-9 and MMP-14 each; b) a ratio of more than 100 for the IC50 values of MMP-1:MMP-2,... Agent: Hoffmann-la Roche Inc. Patent Law Department

20070225254 - Prophylactic and therapeutic treatment of infectious and other diseases with mono- and disaccharide- based compounds: Methods and compositions for treating or ameliorating diseases and other conditions, such as infectious diseases, autoimmune diseases and allergies are provided. The methods employ mono- and disaccharide-based compounds for selectively stimulating immune responses in animals and plants.... Agent: Townsend And Townsend And Crew, LLP

20070225255 - Use of mitochondrially targeted antioxidant in the treatment of liver diseases and epithelial cancers: The present invention relates to the use of a mitochondrially targeted antioxidant, e.g. derivatives of vitamin E, coenzyme Q10 or a glutathione peroxidase mimetic, in the treatment and prevention of liver diseases and/or epithelial cancers. The present invention also relates to pharmaceutical compositions containing the antioxidant(s) intended for such use.... Agent: Wenderoth, Lind & Ponack, L.L.P.

20070225256 - Compound: The present invention provides a compound comprising a steroidal ring system and an optional group R1 selected from any one of —OH, a sulphamate group, a phosphonate group, a thiophosphonate group, a sulphonate group or a sulphonamide group; wherein the A ring of the steroidal ring system is optionally substituted... Agent: Frommer Lawrence & Haug

20070225257 - Derivatives of [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)alkyl] phosphonic acid and methods of use thereof: e

20070225258 - Compositions comprising bisphosphonate and an antifolate: Compositions and methods for the treatment of arthritis, particularly rheumatoid arthritis and osteoarthritis. These compositions include at least one antifolate and at least one bisphosphonate, or pharmaceutically acceptable salts thereof... Agent: Knobbe Martens Olson & Bear LLP

20070225259 - Novel thiazole inhibitors of fructose 1,6-bishosphatase: Compounds of Formula I, their prodrugs and salts, their preparation and their uses are described.... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20070225260 - Amino-propanol derivatives: A compound of formula (I) wherein R1, R2, R3, R4 and R5 are as defined in the specification, processes for their production, their uses, in particular in transplantation, and pharmaceutical compositions containing them.... Agent: Novartis Corporate Intellectual Property

20070225261 - Side-chain variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers: Methods of treating or suppressing mitochondrial diseases, such as Friedreich's ataxia (FRDA), Leber's Hereditary Optic Neuropathy (LHON), mitochondrial myopathy, encephalopathy, lactacidosis, stroke (MELAS), or Kearns-Sayre Syndrome (KSS) are disclosed, as well as compounds useful in the methods of the invention. Methods and compounds useful in treating other disorders are also... Agent: Morrison & Foerster LLP

20070225262 - Method for the treatment of acne: A method for treatment of acne with tetracyclines is provided. A lower sustained dose and no loading dose is employed, with an optional once-a-day dosing regimen.... Agent: Knobbe Martens Olson & Bear LLP

20070225263 - Use of non-feminizing estrogens as retinoprotective agents for the treatment of glaucoma: The invention provides pharmaceutical compositions containing non-feminizing estrogen and methods of using these compositions to prevent or ameliorate retinal and optic nerve damage associated with glaucoma.... Agent: Alcon

20070225264 - Drug delivery means: The invention broadly comprises a chemical composition including a plurality of cholesteryl esters arranged to form a vesicle. In several embodiments, all of the plurality of cholesteryl esters have a same molecular length, which in some embodiments provides a vesicle having a generally smooth outer surface, while in other embodiments,... Agent: Robert C. Atkinson Simpson & Simpson, PLLC

20070225267 - 3-(2-acylamino-1-hydroxyethyl)-morpholine derivatives and their use as bace inhibitors: The present invention provides BACE inhibitors of Formula (I); methods for their use and preparation, and intermediates useful for their preparation.... Agent: Eli Lilly & Company

20070225265 - Novel macrocycles for the treatment of cancer: The present invention relates to new macrocycles of the general formula (I) as their use for the treatment of cancer diseases.... Agent: Edwards Angell Palmer & Dodge LLP

20070225266 - Spiropiperidylrifamycins for the treatment of mycobacterial infections: The compounds of formula (1), their pharmaceutically acceptable salts and their solvates, wherein R1 is a radical selected between hydrogen and alkyl; R2 is selected from hydroxyalkyl, phenyl, phenyl mono-substituted and phenyl di-substituted in positions 3 and 4; R3 is selected from phenyl, phenyl mono-substituted and phenyl di-substituted in positions... Agent: Berenbaum, Weinshienk & Eason, P.c

20070225268 - Method to treat neoplasms via gadolinium stereotactic synchrotron radiation: Described is a method of inhibiting the growth of neoplastic cells. The method includes the steps of contacting neoplastic cells with a gadolinium-containing compound for a time sufficient to allow the gadolinium-containing compound to be internalized within the neoplastic cells. The neoplastic cells are then exposed to a photon flux... Agent: Intellectual Property Department Dewitt Ross & Stevens S.c.

20070225271 - Pyrimidine, quinazoline, pteridine and triazine derivatives: wherein A, R1 to R5 and G are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The invention further relates to pharmaceutical compositions containing such compounds, to a process for their preparation and to their use for the treatment and/or prevention of diseases which are associated... Agent: Hoffmann-la Roche Inc. Patent Law Department

20070225270 - Pyrazolopyrimidines as cyclin dependent kinase inhibitors: In its many embodiments, the present invention provides a novel class of pyrazolo[1,5-a]pyrimidine compounds as inhibitors of cyclin dependent kinases, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition,... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20070225269 - Use of (3-(1-(3-phenyl-propenyl)-piperidin-4-yl)-2,3-dihydro-indol-1-yl)-(pyridin-4-yl)-methanonone derivatives and related compounds as insecticides: The use of a compound of formula (I): R3 N YR1(I) wherein Y is a single bond, C═O, C═S or S(O)71 where m is 0, 1 or 2; R1, R2, R3, R4, R8 and Ra are specified organic groups and p is 0, 1, 2, 3, 4, 5 or 6;... Agent: Syngenta Crop Protection , Inc. Patent And Trademark Department

20070225272 - Cgrp receptor antagonists: (where variables R1, R2, R3, R4, A, B, G, J, Q, T, U, V, W, X and Y are as defined herein) useful as antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as headache, migraine and cluster headache.... Agent: Merck And Co., Inc

20070225273 - Malonamide derivatives: h

20070225274 - Methods for modulating bladder function: This invention provides methods and pharmaceutical compositions for modulating bladder function, and in particular for maintaining bladder control or treating urinary incontinence.... Agent: Choate, Hall & Stewart LLP/wyeth

20070225275 - Tetrahydro-pyrimidoazepines as modulators of trpv1: Certain tetrahydro-pyrimidoazepine compounds are described, which are useful as TRPV1 modulators. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by TRPV1. Thus, the compounds may be-administered to treat, e.g., pain, itch, cough, asthma, or inflammatory bowel disease.... Agent: Philip S. Johnson Johnson & Johnson

20070225276 - 7-phenylsulfonyl-tetrahydro-3-benzazepine dervatives as antipsychotic agents: R3 and R4 independently represent hydrogen or C1-6alkyl; and a pharmaceutically acceptable salt and solvate thereof; with the proviso that the compound {8-[4-(4-fluoro-benzyl)-benzenesulfonyl]-3-methyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl}-dimethyl-amine is excluded. The compounds of formula (I) and pharmaceutically acceptable salts and solvates thereof are useful in therapy, in particular as antipsychotic agents.... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20070225278 - Methods for treating cognitive and other disorders: This invention provides methods and pharmaceutical compositions for treating cognitive disorders such as learning disorders and ADD/ADHD, and other disorders.... Agent: Choate, Hall & Stewart LLP/wyeth

20070225279 - Therapeutic combinations for the treatment of depression: i

20070225277 - Treatment of pain:

20070225280 - Adamantyl-pyrazole carboxamides as inhibitors of 11b-hydroxysteroid dehydrogenase:

20070225281 - 6-amino-1,4-dihydro-benzo[d][1,3]oxazin-2-ones and analogs useful as progesterone receptor modulators: Compounds having the structure of formula I are provided. In formula I, R1 is H, OH, substituted or unsubstituted C1 to C3 alkyl, C1 to C3 perfluoroalkyl, or COR6; R6 is H, substituted or unsubstituted C1 to C4 alkyl, aryl, substituted or unsubstituted C1 to C4 alkoxy, substituted or unsubstituted... Agent: Howson And Howson/wyeth Cathy A. Kodroff

20070225282 - Pyridines and pyridine n-oxides as modulators of thrombin: m

20070225285 - 5-lipoxygenase-activating protein (flap) inhibitors: Described herein are compounds and pharmaceutical compositions containing such compounds, which modulate the activity of 5-lipoxygenase-activating protein (FLAP). Also described herein are methods of using such FLAP modulators, alone and in combination with other compounds, for treating respiratory, cardiovascular, and other leukotriene-dependent or leukotriene mediated conditions or diseases.... Agent: Wilson Sonsini Goodrich & Rosati

20070225283 - Conformationally restricted urea inhibitors of soluble epoxide hydrolase: Inhibitors of the soluble epoxide hydrolase (sEH) are provided that incorporate multiple pharmacophores and are useful in the treatment of diseases.... Agent: Townsend And Townsend And Crew, LLP

20070225284 - Inhibitors of soluble adenylate cyclase: The invention relates to compounds of general formula I as well as the production and use thereof as a medication.... Agent: Millen, White, Zelano & Branigan, P.C.

20070225286 - Compounds and compositions as protein kinase inhibitors: The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of the Abl, BCR-Abl, PDGF-R, trkB, c-SRC, BMX, FGFR3,... Agent: Novartis Corporate Intellectual Property

20070225287 - Substituted arylpyrazines: Arylpyrazine compounds are provided, including arylpyrazines that can bind with high affinity and high selectivity to CRF1 receptors, including human CRF1 receptors. The invention thus includes methods for treatment of disorders and diseases associated with CRF1 receptors, including CNS-related disorders and diseases, particularly affective disorders and diseases, and acute and... Agent: Neurogen Corporation

20070225288 - Indene derivatives and process for the preparation thereof: The inventive indene derivatives of formula (I) are capable of selectively modulating the activities of peroxisome proliferator activated receptors (PPARs), causing no adverse side effects, and thus, they are useful for the treatment and prevention of disorders modulated by PPARs, i.e., metabolic syndromes such as diabetes, obesity, arteriosclerosis, hyperlipidemia, hyperinsulinism... Agent: Anderson, Kill & Olick, P.C.

20070225290 - Tetrahydronaphthalene derivates, processes for preparing them and their use as antiinflammatory agents: e

20070225289 - Topoisomerase-targeting agents: the bond represented by — is a single bond or a double bond, and R1-R5, X, and Y have any of the meanings defined in the specification and their pharmaceutically acceptable salts. The invention also provides pharmaceutical compositions comprising a compound of formula I or II, processes for preparing compounds... Agent: Viksnins Harris & Padys Pllp

20070225291 - Substituted pyrazinone compounds for the treatment of inflammation: Kinase inhibitors of Formula (I): wherein X, Ra, Rb, Rc, and Rd are as defined herein, are disclosed.... Agent: Pfizer Inc.

20070225292 - Therapeutic compounds: pyridine as scaffold: n

20070225293 - Use of c-kit inhibitors for treating fibrosis: The present invention relates to a method for treating fibrosis and related disorders comprising administering a compound capable of depleting mast cell or a compound inhibiting mast cells degranulation, to a human in need of such treatment. Such compounds can be chosen from c-kit inhibitors and more particularly non-toxic, selective... Agent: Foley And Lardner LLP Suite 500

20070225294 - Thiazole and oxazole derivatives as activators of human peroxisome proliferator activated receptors: wherein R1-R5, R25, R26, Y, y, and X2 are as defined herein. The compounds activate human peroxisome proliferater activated receptors (hPPARs) and are useful for the treatment of associated disorders such as dyslipidemia, syndrome X, hypercholesteremia, type II diabetes mellitus, type I diabetes, insulin resistance, hyperlipidemia, and obesity.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B475

20070225295 - Ziprasidone hydrochloride polymorph and process for its preparation: New crystalline form of ziprasidone hydrochloride hemihydrate, process for its preparation, its use for the purification of ziprasidone, its pharmaceutical compositions and their use in therapy.... Agent: Gifford, Krass, Sprinkle,anderson & Citkowski, P.c

20070225296 - Arylalkylamine compound and process for preparing the same: w

20070225297 - Deuterated hepatitis c protease inhibitors:

20070225298 - Method for controlling fungi and mites in textile substrates: The present invention, therefore, relates to a method for prophylaxis, control or reduction of fungi in a textile substrate, which comprises applying to a textile substrate that is susceptible to fungal infestation an amount effective for the prophylaxis, control or reduction of fungi of at least one fungicidal compound. The... Agent: Syngenta Crop Protection , Inc. Patent And Trademark Department

20070225299 - Novel combination containing a stimulator of soluble guanylate cyclase and a lipid-lowering substance: A combination product which comprises as pharmaceutically active ingredients at least one active ingredient component A and at least one active ingredient component B, where active ingredient component A is a direct soluble guanylate cyclase stimulator of the formula (I) and active ingredient component B is a lipid-lowering agent, is... Agent: Jeffrey M. Greenman

20070225301 - Treatment of acne and other diseases: The invention relates to compounds for the treatment of dermatological diseases where inflammation, matrix metalloproteinases (MMPs) and peroxisome proliferator-activated receptors (PPARs) play a role in mediating the disease, such as the treatment of acne with Pemirolast or a closely related compound thereof.... Agent: Foley And Lardner LLP Suite 500

20070225300 - Heteroaryl substituted 2-pyridinyl and 2-pyrimidinyl -6,7,8,9-tetrahydropyrimido[1,2-a] pyrimidin-4-one derivatives: X, Y, R1, R2, R3, R4, R5, m, n and p are as defined herein. In particular, the invention relates to a medicament comprising the said derivative or a salt thereof as an active ingredient which is used for preventive and/or therapeutic treatment of a neurodegenerative disease caused by abnormal... Agent: Ross J. Oehler Sanofi-aventis U.s. LLC

20070225302 - 2-amino-9-[(2-hydroxymethyl) cyclopropylidenemethyl] purines as antiviral agents:

20070225303 - 8-oxoadenine compound: X1 is oxygen atom, Z is straight or branched chain alkylene, and R1 is an alkyl group which is optionally substituted by hydroxy group, an alkoxy group, alkoxycarbonyl group and so on, or its pharmaceutically acceptable salt.... Agent: Birch Stewart Kolasch & Birch

20070225304 - Aminopurine derivatives for treating neurodegenerative diseases: The invention relates to aminopurine derivatives useful in treating disorders that are mediated by adenosine receptor function, including neurodegenerative diseases and inflammation. The compounds are of the general formula:... Agent: Heslin Rothenberg Farley & Mesiti PC

20070225305 - Preparation of ester of purine derivatives: A process for the preparation of valganciclovir with triacetyl ganciclovir (V) as a starting material, comprising the following steps: selective hydrolysis, reacting with a coupling agent and a solvent, followed by hydrolysis under basic conditions and hydrogenolysis in the presence of a catalyst.... Agent: Hedman & Costigan P.C.

20070225306 - Compounds and compositions as protein kinase inhibitors: The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of the FAK, Abl, BCR-Abl, PDGF-R, c-Kit, NPM-ALK, Flt-3,... Agent: Genomics Institute Of The Novartis Research Foundation

20070225307 - C-met modulators and method of use: The present invention provides compounds for modulating protein kinase enzymatic activity for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration and chemoinvasion. More specifically, the invention provides quinazolines and quinolines which inhibit, regulate, and/or modulate kinase receptor, particularly c-Met, KDF, c-Kit, flt-3 and flt-4, signal transduction pathways... Agent: Leydig Voit & Mayer, Ltd

20070225308 - 2-amino quinazoline derivative: e

20070225309 - Substituted thiatriazaacenaphthylene-6-carbonitrile kinase inhibitors:

20070225310 - Antiviral methods and compositions: Disclosed herein are antiviral compounds, such as anti-human cytomegalovirus antiviral compounds, pharmaceutical compositions and antiviral methods.... Agent: Foley Hoag, LLP Patent Group (w/huv Hmv)

20070225311 - 7-t-butoxyiminomethylcamptothecin conjugated in position 20 with integrin antagonists: in which the R1 group is as defined in the specification and includes the condensation of 7-t-butoxyiminomethylcamptothecin in position 20 with a cyclopeptide containing the RGD sequence. Said compounds are endowed both with high affinity for integrin receptors αvβ3 and αvβ5 and with selective cytotoxic activity on human tumour cell... Agent: Nixon & Vanderhye, PC

20070225312 - Terguride / proterguride for the treatment of chronic pain: The present invention relates to the use of terguride and proterguride for the prophylaxis and/or the treatment of chronic pain conditions as well as to pharmaceutical compositions comprising terguride and/or proterguride optionally together with an opiate analgesic.... Agent: J C Patents, Inc.

20070225313 - Epimers and isomers of tetrazole containing rapamycin analogs, methods of making and using the same: Epimers and isomers of tetrazole-containing rapamycin analogs and a pharmaceutically acceptable salt or prodrug thereof, are immunomodulatory agents and are useful in the treatment of restenosis and immune and autoimmune diseases. Also disclosed are cancer-, fungal growth-, restenosis-, post-transplant tissue rejection- and immune- and autoimmune disease-inhibiting compositions and a method... Agent: Philip S. Johnson Johnson & Johnson

20070225316 - Methods and compositions for treating schizophrenia: The present invention relates to methods and compositions useful for treating, preventing and/or delaying the onset and/or development of schizophrenia by administering a hydrogenated pyrido[4,3-b]indole, such as dimebon, or a pharmaceutically acceptable salt thereof, to an individual.... Agent: Morrison & Foerster LLP

20070225315 - Methods of treating muscular wasting diseases using nf-kb activation inhibitors: Methods for treating muscular wasting diseases such as Duchenne muscular dystrophy are disclosed. Specifically, the methods include administering to a subject in need of treatment for a muscular wasting disease, an NF-κB activation inhibitor capable of blocking the activation of NF-κB.... Agent: Senniger Powers

20070225314 - Novel forms of tiotropium bromide and processes for preparation thereof: This invention relates to novel crystalline forms of tiotropium bromide, processes for preparing them, and their use in pharmaceutical formulations.... Agent: Lerner, David, Littenberg, Krumholz & Mentlik

20070225317 - Rsv polymerase inhibitors: i

20070225319 - Piperidinyl indole and tetrohydropyridinyl indole derivatives and methods of their use: 3-Piperidin-4-yl-1H-indole and 3-(1,2,3,6-tetrahydro-pyridin-4-yl)-1H-indole derivatives are disclosed. Methods of using the derivatives and compositions containing the derivatives in the prevention and/or treatment of serotonin disorders, such as depression and anxiety, are also disclosed. Additionally, processes for the preparation of 3-piperidin-4-yl-1H-indole and 3-(1,2,3,6-tetrahydro-pyridin-4-yl)-1H-indole derivatives are disclosed.... Agent: Woodcock Washburn LLP/wyeth

20070225318 - Pyrazole compounds useful in the treatment of inflammation: There is provided compounds of formula (I), wherein R1, R2, Ra and Rb have meanings given in the description, and pharmaceutically-acceptable salts thereof, which compounds are useful in the treatment of diseases in which inhibition of the activity of a lipoxygenase (e.g. 15-lipoxygenase) is desired and/or required, and particularly in... Agent: Morgan Lewis & Bockius LLP

20070225320 - Process for preparing clopidogrel: A process for preparing clopidogrel or a salt thereof.... Agent: Dr. Reddy's Laboratories, Inc.

20070225321 - 2,4-pyrimidinediamine compounds and their uses: The present invention provides 2,4-pyrimidinediamine compounds that inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators, intermediates and methods of synthesizing the compounds and methods of using the compounds in a variety of contexts, including in the treatment and prevention of diseases characterized... Agent: Rigel Pharmaceuticals Inc.

20070225322 - Compositions and methods for treating middle-of-the night insomnia: The present invention provides compositions and methods for treating middle-of-the-night insomnia without residual sedative effects upon awakening by administering low doses (about 5 mg or less) of zolpidem or a salt thereof.... Agent: O'melveny & Myers LLP

20070225323 - Substituted 4-phenyltetrahyrdoisoquinolines, pharmaceutical compositions thereof, methods for their preparation and therapeutic use: and pharmaceutical compositions comprising them wherein the R groups are herein defined. These are excellent inhibitors of the sodium-hydrogen exchanger (NHE), in particular of the sodium-hydrogen exchanger of subtype 3 (NHE3). As such these compounds are useful in the treatment of various disorders of the renal and respiratory systems such... Agent: Ross J. Oehler Sanofi-aventis U.s. LLC

20070225324 - Bicycloheteroaryl compounds as p2x7 modulators and uses thereof: d

20070225327 - Biaryl sulfonamides and methods for using same: The present invention relates to biaryl sulfonamides and their use as, for example, metalloproteinase inhibitors.... Agent: Woodcock Washburn LLP/wyeth

20070225326 - Montelukast amantadine salt: An amantadine salt of montelukast is useful in purification of montelukast or its salts and as a pharmaceutical active ingredient.... Agent: SynthonIPInc

20070225325 - Solid forms of montelukast acid: Differing forms of 1-(((1(R)-(3-(2-(7-chloro-2-quinolinyl)ethenyl)-phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl)propyl)thio)methyl)cyclopropane acetic acid and methods for synthesizing same.... Agent: Rissman Jobse Hendricks & Oliverio, LLP

20070225329 - Aryl aniline beta2 adrenergic receptor agonists: wherein R1-R13 and w have any of the values described in the specification. The invention also provides combinations of such compounds and other therapeutic agents, pharmaceutical compositions comprising such compounds and combinations, methods of using such compounds to treat diseases associated with β2 adrenergic receptor activity, and processes and intermediates... Agent: Theravance, Inc.

20070225328 - Synthetic nacre: A method of manufacturing sustainable biominerals such as nacre is described. Furthermore, synthetic self-organizing biominerals, in particular synthetic nacre is provided.... Agent: Cooper & Dunham, LLP

20070225330 - Use of certain phenyl-naphthyl compounds that do not have significant affinity to er alpha or er beta for protection of neurons and oligodendrocytes in the treatment of multiple sclerosis: The invention provides a new use for certain SERM-like phenylnaphthyl compounds that do not exhibit affinity for alpha or beta type estrogen receptors (ER) in the treatment of multiple sclerosis.... Agent: Ross J. Oehler Sanofi-aventis U.s. LLC

20070225331 - 4,4-disubstituted piperidines, and methods of use thereof: One aspect of the present invention relates to heterocyclic compounds. A second aspect of the present invention relates to the use of the heterocyclic compounds as ligands for various mammalian cellular receptors, including dopamine transporters. The compounds of the present invention will find use in the treatment of numerous ailments,... Agent: Edwards Angell Palmer & Dodge, LLP

20070225332 - Novel acetyl-coa carboxylase (acc) inhibitors and their use in diabetes, obesity and metabolic syndrome: e

20070225333 - 3-heterocyclyl-4-phenyl-triazole derivatives as inhibitors of the vasopressin via receptor: Compounds of formula (I): or a pharmaceutically acceptable derivative thereof, wherein R represents C1-6alkyl (optionally substituted by C1-6alkyloxy or Het) or C1-6alkyloxy; R1 and R2 independently represent hydrogen, halo or C1-6alkyl, ring A represents Het1; X represents O or NR3; R3 represents hydrogen or C1-6alkyl; ring B represents a phenyl... Agent: Pfizer Inc.

20070225334 - Methods for treating cognitive and other disorders: This invention provides methods and pharmaceutical compositions for treating cognitive disorders such as learning disorders, ADD/ADHD, and other disorders.... Agent: Choate, Hall & Stewart LLP/wyeth

20070225336 - Anthropodicidal anthranilamides: R1, R2, R3, R4a, R4b and R5 are as defined in the disclosure. Also disclosed are methods for controlling invertebrate pests comprising contacting the invertebrate pests or their environment with a biologically effective amount of a compound of Formula 1 or a composition comprising a compound of Formula 1.... Agent: E I Du Pont De Nemours And Company Legal Patent Records Center

20070225335 - Pyrazole derivatives for treating condit ions mediated by activation of the adeno sine a2b or a3 receptor: in free or salt form, wherein R1, R2, R3 and R4 have the meanings as indicated in the specification, are useful for treating a condition mediated by activation of the adenosine A2b receptor or the adenosine A3 receptor, particularly an inflammatory or obstructive airways disease. Pharmaceutical compositions that contain the... Agent: Novartis Corporate Intellectual Property

20070225337 - Novel co-precipitate of amorphous rosiglitazone: A novel coprecipitate of amorphous rosiglitazone maleate with a pharmaceutically acceptable carrier, e.g. polyvinylpyrolidone, mannitol, lactose, methylcellulose, cyclodextrin or silicon dioxide, a process for the preparation of said novel co-precipitate and the use of said novel coprecipitate of amorphous rosiglitazone with a pharmaceutically acceptable carrier in the treatment and/or prophylaxis... Agent: Novartis Corporate Intellectual Property

20070225338 - Juvenile hormone analogs for control of leafhopper and treehopper pests: The present invention pertains to compounds and methods for controlling treehopper and leafhopper pests, such as the glassy-winged sharpshooter (GWSS), while conserving their parasites (such as parasitoid wasps). In one embodiment, the compound is a juvenile hormone analog such as methoprene, kinoprene, and hydropene. The invention also concerns pesticidal compositions... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20070225339 - Compositions and methods for treating rheumatoid arthritis: The present invention relates to methods and compositions for treating RA in subjects in need thereof. The invention also relates to kits and pharmaceutical packs comprising compositions and dosage forms.... Agent: Vertex Pharmaceuticals Inc.

20070225340 - Phenyl compounds and their use in the treatment of conditions mediated by the action of pge2 at the ep1 receptor: e

20070225341 - Nicotinic acid compositions for treating hyperlipidemia and related methods therefor: An orally administered antihyperlipidemia composition according to the present invention includes from about 250 to about 3000 parts by weight of nicotinic acid, and from about 5 to about 50 parts by weight of hydroxypropyl methylcellulose. Also, a method of treating hyperlipidemia in a hyper lipidemic having a substantially periodic... Agent: Dykema Gossett PLLC

20070225342 - Nicotinic acid compositions for treating hyperlipidemia and related methods therefor: An orally administered antihyperlipidemia composition according to the present invention includes from about 250 to about 3000 parts by weight of nicotinic acid, and from about 5 to about 50 parts by weight of hydroxypropyl methylcellulose. Also, a method of treating hyperlipidemia in a hyper lipidemic having a substantially periodic... Agent: Dykema Gossett PLLC

20070225343 - Pharmaceutical latrunculin formulations: The present invention relates to an aqueous pharmaceutical formulation comprising at least one latrunculin and the formulation does not contain a substantial amount of dimethyl sulfoxide. In one embodiment, the present invention is directed to an aqueous pharmaceutical formulation comprising at least one latrunculin in an amount of 0.001-2% w/v,... Agent: Howery LLP

20070225344 - Sulfonamide derivatives to treat infection with hepatitis c virus: e

20070225345 - Therapeutic substituted cyclopentanones:

20070225346 - Crystalline forms: A salt of the compound N-{2-tert-butyl-1-[(4,4-difluorocyclohexyl)methyl]-1H-benzimidazol-5-yl}ethanesulfonamide, which is an ethanesulphonic acid salt, a sulphuric acid salt, an ethane disulphonic acid salt, a hydrochloric acid salt, a hydrobromic acid salt, a phosphoric acid salt, an acetic acid salt, a fumaric acid salt, a maleic acid salt, a tartaric acid salt, a... Agent: Astra Zeneca Pharmaceuticals Lp Global Intellectual Property

20070225347 - Imidazole derivatives: Compounds of the formula (I), in which R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, X and X′ have the meanings indicated in claim 1, are inhibitors of tyrosine kinases, in particular TIE-2, and Raf kinases and can be employed, inter alia, for the treatment of tumours.... Agent: Baker & Daniels LLP

20070225348 - Amino acid composition for improving glucose tolerance: Disclosed are compositions, including low-calorie beverages or liquids, comprising isoleucine, leucine, valine, cysteine, and methionine, in specified amounts, weight ratios, or both. The compositions are especially useful in treating individuals afflicted with impaired glucose tolerance or diabetes.... Agent: Ross Products Division Of Abbott Laboratories Department 108140-ds/1

20070225349 - Substituted 4-(indazol-3-yl)phenols: R1, R2, R3, R4, R5, R6, R7, R8, R9, and R10 are as defined in the specification or a pharmaceutically acceptable salt thereof which are useful for the treatment of the inflammatory component of diseases and are particularly useful in treating atherosclerosis, myocardial infarction, congestive heart failure, inflammatory bowel disease,... Agent: Woodcock Washburn LLP/wyeth

20070225350 - Compositions and methods for treating neoplastic diseases: Disclosed herein are compositions and methods for treating neoplastic diseases. Included are compositions and methods that are effective against multiple myeloma cells resistant to conventional and bortezomib treatment. Furthermore, combination treatment with two different proteosome inhibitors is shown to be synergistic for treating multiple myeloma.... Agent: Knobbe Martens Olson & Bear LLP

20070225351 - Methods and compositions for controlling body weight and appetite: The present invention provides novel compositions and methods for the controlling appetite and weight and/or treating obesity using a (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane or related compound. The invention also provides novel compositions and methods for treating or preventing disorders related to or complicated by excessive body weight or obesity, including coronary heart disease,... Agent: Black Lowe & Graham PLLC Jeffrey J. King, Esq.

20070225352 - Novel androgens: e

20070225353 - Process for forming amorphous atorvastatin: Forming amorphous atorvastatin comprises the steps of dissolving atorvastatin in a solvent to form a solution, followed by adding the solution to a mixture comprising a non-solvent and a hydroxylic solvent to afford amorphous atorvastatin.... Agent: Warner-lambert Company

20070225355 - Dietary compositions for enhancing metabolism and reducing reactive oxygen species: This invention relates to dietary compositions and to methods for modifying cellular metabolism, metabolic production of reactive oxygen species and the resulting level of reactive oxygen species. The invention is drawn to a composition comprising a combination of carnitine, lipoic acid and polyphenol, which has the effect of enhancing metabolism... Agent: Conwell LLC

20070225354 - Use of dihydrolipoamide for enhancing physical performance: A method of decreasing fat and adipose tissue, reducing appetite and increasing alertness in humans comprises administering dihydrolipoamide in a daily dosage between about 300 and 2000 mg. Dihydrolipoamide may be administered once per day or in multiple doses, either alone or in combination with other compounds and mixtures.... Agent: Miller, Canfield, Paddock And Stone P.L.C C/o Robert Kelley Roth

20070225356 - Preventive and/or therapeutic agent for chronic sinusitis: m

20070225359 - Dimeric compounds and their use as anti-viral agents: The invention relates to compounds of general formula (I); in which R is an amino or guanidino group; R2 is acetyl or trifluoroacetyl; and n is an integer from 10 to 18 or a pharmaceutically acceptable derivative thereof, methods for their preparation, pharmaceutical formulations containing them or their use in... Agent: Foley And Lardner LLP Suite 500

20070225358 - Dimeric compounds and thier use as anti-viral agents: The invention relates to compounds of general formula (I); in which R is an amino or guanidino group; R2 is acetyl or trifluoroacetyl; X is CONH, NHCO or O; n is an integer from 2 to 6; and Y is C2-C9 alkyl C3-8 cycloalkyl, C1-C4 alkoxyalkyl, an amino acid or... Agent: Foley And Lardner LLP Suite 500

20070225357 - Formulation for stimulating hair growth: The present invention is directed to a topical formulation comprising the Compound 6-[[(3S,4R)-3,4-dihydro-3-hydroxy-6-[(3-hydroxyphenyl)sulfonyl)-2,2,3-trimethyl-2H-1-benzopyran-4-yl]oxy]-2-methyl-3(2H)-pyridazinone in a formulation comprising at least one pharmaceutically acceptable carrier. Particularly, the formulation may be used to promote hair growth, including alleviating alopecia.... Agent: Warner-lambert Company

20070225360 - Anti-aging composition containing phloretin: An anti-aging composition containing: (a) at least one first active ingredient chosen from phloretin and its derivatives; (b) at least one second active ingredient chosen from cinnamic acid, resveratrol, retinol, ascorbic acid, tocopherol, and their derivatives; and (c) at least one non-aqueous organic solvent, with the proviso that if the... Agent: L'oreal Usa/ Patent Department

20070225361 - Dimeric compounds and their use as anti-viral agents: The invention relates to compounds of general formula (I), in which: R is an amino or guanidino group; R2 is acetyl or trifluoroacetyl; n and q are either the same or different and selected from 0, 1 or 2; and X is an optionally substituted phenyl, optionally substituted naphthyl or... Agent: Foley And Lardner LLP Suite 500

20070225362 - Compounds, compositions and methods for the treatment of amyloid diseases such as systemic aa amyloidosis: Bis- and tris-dihydroxyaryl compounds and their methylenedioxy analogs and pharmaceutically acceptable esters, their synthesis, pharmaceutical compositions containing them, and their use in the treatment of amyloid diseases, especially Aβ amyloidosis, such as observed in Alzheimer's disease, IAPP amyloidosis, such as observed in type 2 diabetes, AA/SAA amyloidosis, such as observed... Agent: Proteotech, Inc.

20070225363 - Methods and agents for inhibiting dynamin-dependent endocytosis: There are disclosed methods for inhibiting dynamin-dependent endocytosis in cells comprising treating the cells with an effective amount of a compound of formula (I), or a dimeric tyrphostin, physiologically acceptable salt, or prodrug thereof. Compounds useful in the methods described are also provided. The inhibition of dynamin-dependent endocytosis of cells... Agent: Edwards Angell Palmer & Dodge LLP

20070225364 - Use of bismuth subgallate and borneol in treating melanoma: A new use of bismuth subgallate and borneol for treating melanoma by the reduction of the number of melanoma cells and/or the inhibition of the proliferation of melanoma cells is provided. A use of bismuth subgallate and borneol for inhibiting the migration of melanoma cells is also provided.... Agent: Ladas & Parry

20070225365 - Cetp inhibitors: Compounds of Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis. In the compounds of Formula 1, A1 and A2 are each an aromatic ring, a 5-6-membered heterocyclic ring, an aromatic ring fused... Agent: Merck And Co., Inc

20070225366 - Levodopa prodrug mesylate, compositions thereof, and uses thereof: (2R)-2-Phenylcarbonyloxypropyl(2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoate mesylate and crystalline form thereof, methods of making the same, pharmaceutical compositions thereof, and methods of using the same to treat diseases or disorders such as Parkinson's disease are provided.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070225367 - Composition for beneficially influencing alzheimer's disease and/or for alzheimer's prophylaxis: The invention relates to a composition for Alzheimer's prophylaxis and/or for therapeutic treatment of pre-existing symptoms of the type of Alzheimer's disease comprising a mixture of VLCFA3, in particular based on montan waxes and/or derivatives thereof or Guerbet acids or the corresponding components of carnauba wax, shellac or policosanols or... Agent: Clariant Corporation Intellectual Property Department

20070225368 - Therapy for multiple sclerosis: The invention relates to a method of ameliorating multiple sclerosis and/or the symptoms of multiple sclerosis in a mammal, which comprises administering or having self administered to the mammal an effective amount of (a) cetyl myristate or (b) cetyl myristate and cetyl palmitate. In preferred embodiments the mode of administration... Agent: Jacobson Holman PLLC

20070225369 - Ophthalmic composition for treating tear dysfunction: There are provided an ophthalmic composition that comprises 3-hydroxybutyric acid and/or salts thereof as active ingredients and is used to prevent desiccation of eyes and an ophthalmic composition that is used to treat tear dysfunction. By use of the ophthalmic compositions of the present invention, desiccation of the eyes can... Agent: Birch Stewart Kolasch & Birch

20070225370 - Nutritional compositions and methods: The invention is an anti-inflammatory composition comprising a mixture comprising two components, a first component rich in EPA and a second component rich in GLA. The first component is a mixture comprising EPA and preferably DHA comprising at least 35% EPA, preferably 50% EPA and more preferably 60% or more... Agent: Foothill Law Group

20070225371 - Dermatological composition containing alkyl ureas: This invention relates to a method for topically treating dermal disorders employing a composition comprising a mixture of urea and a safe and effective amount of an alkyl urea in a therapeutically effective ratio. The urea and alkyl urea are blended with a carrier suitable for topical application to dermal... Agent: Jerry Zhang

20070225372 - Amides as bace inhibitors: The present invention provides BRACE inhibitors of Formula (I): methods for their use, and intermediates and methods for their preparation.... Agent: Eli Lilly & Company

20070225373 - Zn2motif-tethered short-chain fatty acids as a novel class of histone deacetylase: Zn2+-chelating motif-tethered fatty acids as histone deacetylase (HDAC) inhibitors. One hydroxamate-tethered phenylbutyrate compound, N-hydroxy-4-(4-phenylbutyrylamino)-benzamide (HTPB), displayed nM potency in inhibiting HDAC activity. Exposure of several cancer cell lines to HTPB at sub-μM concentrations showed reduced cell proliferation accompanied by histone hyperacetylation and elevated p21WAF/CIP1 expression, hallmark features associated with intracellular... Agent: Calfee Halter & Griswold, LLP

20070225374 - Hydroxypropyl amides for the treatment of alzheimer's disease: The present invention relates to compounds of formula (I) useful in treating Alzheimer's disease and other similar diseases. These compounds include inhibitors of the beta-secretase enzyme that are useful in the treatment of Alzheimer's disease and other diseases characterized by deposition of A beta peptide in a mammal. The compounds... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20070225375 - Methods of treating fibromyalgia syndrome, chronic fatigue syndrome and pain: The present invention provides a method of treating fibromyalgia syndrome (FMS), chronic fatigue syndrome (CFS), and pain in an animal subject. The method generally involves administering a therapeutically effective amount of a dual serotonin norepinephrine reuptake inhibitor compound or a pharmaceutically acceptable salt thereof, wherein said dual serotonin norepinephrine reuptake... Agent: Darby & Darby P.C.

20070225376 - Medicinal agent: Medicine and pharmacology, in particular a medicinal agent exhibiting anti-tumoral and immunomodulatory actions and including a tri-p-amino-thiphenyl-chlormethan tetramethylated, pentamethylated or hexamethylated derivative, the mixtures thereof or the combination thereof with dextrin. The agent of this invention exhibits a high activity and a reduced side effect.... Agent: Pauley Petersen & Erickson

20070225377 - Bridged ring structures as pharmaceutical agents: The present invention is directed to 1α,25-dihydroxyvitamin D3 mimics which modulate the vitamin D receptor (VDR). The invention is further directed to pharmaceutical compositions and methods for the treatment, prevention or amelioration of one or more symptoms of disease or disorder related to the activity of the vitamin D receptor... Agent: Mcdonnell Boehnen Hulbert @ Berghoff LLP

20070225378 - Menthol dearivative and cooling agent composition comprising the same: The invention relates to innovative menthol derivatives which are represented by the general formula (I) below and are excellent in a cooling effect and cool retaining effect, cooling agent compositions comprising the menthol derivatives, and sensory stimulation agent compositions containing the cooling agent compositions, as well as fragrance compositions, beverage... Agent: Mcdermott Will & Emery LLP

20070225379 - Transdermal delivery of systemically active central nervous system drugs: The invention relates to a transdermal or transmucosal non-occlusive, semi-solid pharmaceutical formulation that includes at least one systemically active agent that acts on the Central Nervous System (CNS) of a mammal; and a permeation enhancing solvent system present in an amount sufficient to solubilize the at least one active ingredient.... Agent: Winston & Strawn LLP Patent Department

20070225380 - Parakeratosis inhibitor and skin preparation for external use: To provide a parakeratosis inhibitor, pore reducing agent and skin roughness preventing/ameliorating agent that exhibit capabilities of parakeratosis inhibition, pore reduction, skin roughness prevention/amelioration, etc., and further provide a skin preparation for external use having these capabilities. There are provide a parakeratosis inhibitor and a pore reducing agent each comprising... Agent: Snider & Associates

20070219127 - Cyclosporin a compositions: A composition comprising cyclosporin A and a nonaqueous, physiologically acceptable liquid carrier, said composition being suitable for topical administration to an eye of a mammal is disclosed herein. Methods of treating disease related thereto are also disclosed.... Agent: Allergan, Inc.

20070219160 - Process tolerant starch composition with high total dietary fiber content: The present invention relates to a starch composition with high total dietary fiber (TDF) that retains its TDF upon processing. In particular, over 50% of such fiber is retained upon extrusion processing. Such starch is useful in the manufacture of high fiber food products, including extruded products such as breakfast... Agent: National Starch And Chemical Company

20070219117 - Bidentate motif and methods of use: e

20070219116 - Follicle stimulating hormone superagonists: This invention provides superactive analogs of FSH demonstrating enhanced bioactivity both in vitro and in vivo as compared to wild type FSH. In particular, the analogs of the invention demonstrate at least a ten fold increase in potency or at least a ten percent increase in maximal efficacy as compared... Agent: Cooley Godward Kronish LLP Attn: Patent Group

20070219119 - Method of treatment of tendonitis by administration of streptolysin o: The invention provides a method for administering streptolysin O for treatment of various conditions including connective tissue disorders, reproductive fibroses and conditions mediated by the CD44 receptor. The invention also provides methods for protecting nerve cells from the effects of neurotoxic agents by the administration of streptolysin O.... Agent: Marshall, Gerstein & Borun LLP

20070219120 - Methods for treating inflammatory disease by administering aldehydes and derivatives thereof: A method is disclosed for treating inflammatory disease in an animal in need thereof by administering to the animal a pharmaceutical composition containing an anti-inflammatory effective amount of an organic aldehyde compound or a derivative thereof in a pharmaceutically acceptable vehicle.... Agent: Wilmer Cutler Pickering Hale And Dorr LLP

20070219115 - Pharmaceutical uses of bisphosphonates: A method of treating a patient suffering from a malignant disease comprising administering to the patient an effective amount of a chemotherapeutic agent selected from the group consisting of: taxol, a derivative thereof and letrozole, followed sequentially by an effective amount of a bisphosphonate. The invention further provides a method... Agent: Novartis Corporate Intellectual Property

20070219114 - Preventives or remedies for hepatopathy: The present invention relates to a preventive or a therapeutic agent for hepatopathy, comprising, as an effective ingredient, a polypeptide derivative having an activity of binding to growth hormone secretagogue receptor and thus elevating intracellular calcium ion concentration, and having one amino acid sequence selected from the group consisting of... Agent: Hunton & Williams LLP Intellectual Property Department

20070219118 - Therapeutic methods for nucleic acid delivery vehicles: It has been found that certain synthetic vectors and nucleic acid sequences that encode viral genomic sequences can, for example, be administered to a subject repeatedly as a vehicle for effectively delivering one or more therapeutic nucleic acid molecules or polypeptides to a cell or tissue. Accordingly, the disclosed nucleic... Agent: Fish & NeaveIPGroup Ropes & Gray LLP

20070219121 - Vasodilator pharmaceutical preparation and health food composition: This invention provides a novel material having a vasodilator action thereby suppressing or ameliorating various human diseases and disorders. A composition comprising, as an active ingredient, peptides obtained by hydrolyzing proteins such as proteins derived from a seaweed selected from layer, wakame, edible brown algae, sea tangle, chlorella and spirulina,... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070219122 - Modified triple-helix forming oligonucleotides for targeted mutagenesis: High affinity, chemically modified triplex-forming oligonucleotides (TFOs) and methods for use thereof are disclosed. TFOs are defined as triplex-forming oligonucleotides which bind as third strands to duplex DNA in a sequence specific manner. Triplex-forming oligonucleotides may be comprised of any possible combination of nucleotides and modified nucleotides. Modified nucleotides may... Agent: Patrea L. Pabst Pabst Patent Group LLP

20070219126 - Class of bioactive glycoprotein: The invention relates to a bioactive chemical composition, more specifically to proteins and can be used in medicine, veterinary and cell biology. The invented glycoproteins are extracted with the help of isoelectric focusing from intercellular space of tissues taken from different organs, blood serum and bile of the vertebrates (human... Agent: Jacobson Holman PLLC

20070219124 - Lipopeptide compositions: The invention relates to a pharmaceutical composition comprising as an active agent a lipopeptide in a physiologically effective dose and a cyclodextrin or a cyclodextrin derivative.... Agent: Mayer & Williams PC

20070219125 - Novel thrombospondin-1 polynucleotides encoding variant thrombospondin-1 polypeptides and methods using same: Novel polypeptides and polynucleotides encoding same are provided. Also provided methods and phamaceutical compositions which can be used to treat various disorders such as cancer and retinopathies, using the polypeptides and polynucleotides of the present invention.... Agent: Staas & Halsey LLP

20070219123 - Selective n-acylation of a82846 glycopeptide analogs: The present invention provides a process for selectively acylating an A82846A, A82846B, A82846C or PA-42867-A glycopeptide at the N1, N2 or N3 positions and the monoacylated compounds prepared therefrom.... Agent: Merchant & Gould PC

20070219132 - Black bear parathyroid hormone and methods of using black bear parathyroid hormone: Black bear parathyroid hormone (PTH) and functional fragments thereof are provided. Also provided are methods of using black bear PTH and functional fragments for increasing cAMP in a bone-forming cell; reducing apoptosis in a bone-forming cell; decreasing the ratio of expression levels of Bax protein to Bcl-2 protein in a... Agent: Michael Best & Friedrich, LLP

20070219133 - Cd52 optimized fc variants and methods for their generation: The present invention relates to CD52 optimized Fc variants, methods for their generation, and antibodies and Fc fusions comprising optimized Fc variants.... Agent: Morgan, Lewis & Bockius, LLP

20070219131 - Compositions capable of facilitating penetration across a biological barrier: This invention relates to novel penetrating compositions including one or more effectors included within a water soluble composition, immersed in a hydrophobic medium. The invention also relates to methods of treating or preventing diseases by administering such penetrating compositions to affected subjects.... Agent: Fish & Richardson PC

20070219129 - Hsp90 decoy peptides and uses thereof: A method of inhibiting hsp90 association with eNOS in a patient, comprising the step of treating a patient with an effective amount of a pharmaceutical composition comprising an hsp90 decoy peptide.... Agent: Quarles & Brady LLP

20070219134 - Lymphatic zip codes in tumors and pre-malignant lesions: Disclosed herein are compositions and methods for and involving selectively targeting tumor lymphatics.... Agent: Needle & Rosenberg, P.C.

20070219128 - Medical and health-care uses of pufferfish type i collagen extract and processes for producing said extract: The present invention relates to the use of pufferfish type I collagen extract as effective ingredient in the manufacture of medicaments and health-care foods for prevention and treatment of the following diseases, wherein the main chemical components and active components of the pufferfish type I collagen extract are natural pufferfish... Agent: Seed Intellectual Property Law Group PLLC

20070219135 - Pharmaceutical composition comprising factor vii polypeptides and pai-1 polypeptide: The present invention relates to a composition comprising factor VII or a factor VII-related polypeptide, and PAI-1 or a PAI-1-related polypeptide, and the use thereof for treating bleeding episodes.... Agent: Novo Nordisk, Inc. Patent Department

20070219130 - Slurp-1 compositions